View More Recent Stories

Sep 6, 2022 07:30AM AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Aug 30, 2022 07:30AM AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma
Aug 18, 2022 09:05AM AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer
Aug 15, 2022 04:09PM AIM ImmunoTech (AIM) Provides Update on Jorgl Activist Group Litigation
Aug 15, 2022 04:05PM AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
Aug 15, 2022 08:05AM AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 28, 2022 09:10AM AIM ImmunoTech (AIM) Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
Jul 28, 2022 09:10AM AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
Jul 20, 2022 08:05AM AIM ImmunoTech (AIM) reports additional patient data from Single-Center Named Patient Program evaluating Ampligen
Jul 20, 2022 08:05AM AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free
Jul 18, 2022 08:00AM AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
Jul 14, 2022 08:05AM AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series
Jun 21, 2022 08:35AM AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing
Jun 16, 2022 05:01PM Descartes Announces Results of Annual Shareholder Meeting and Appointment of Officers
Jun 13, 2022 08:06AM AIM ImmunoTech (AIM) Bolsters Intellectual Property Portfolio for Ampligen with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-1
Jun 13, 2022 08:05AM AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Tr
May 19, 2022 08:00AM AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:06AM AIM ImmunoTech (AIM) Provides Update on Ampligen Long COVID Development Program
May 18, 2022 08:00AM AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program
May 16, 2022 07:05AM AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022 08:05AM AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022
Jan 12, 2022 10:35AM JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
View More Recent Stories